Atypical Femoral Fractures Following Use of Intravenous Zoledronic Acid After Prior Treatment with Alendronate: A Clinical Practice Series and Opinion
Journal Title: International Journal of Medical and Pharmaceutical Case Reports - Year 2017, Vol 10, Issue 2
Abstract
Aims: An increasing number atypical femoral fractures (AFFs) have been reported in patients who have taken bisphosphonates (BPs) for several years. The European Medicines Agency (EMA) concluded in 2011 that these fractures were a class effect of the drugs. The United States Food & Drug Administration (FDA) updated labels for currently proprietary intravenous Reclast™ (zoledronic acid) have, since 2015, agreed with the EMA opinion. Section 17 of the FDA label states Reclast™ “can cause” these fractures. In this report, we present a clinical sub-class of cases of these fractures illustrating the potential for harm associated with switching BP therapy from an oral agent to Reclast™ (zoledronic acid). Methodology: This paper presents 6 long-term case descriptions of patients, diagnosed with either osteopenia or osteoporosis, incurring a total of ten AFFs following a switch to intravenous zoledronic acid after a much longer and uncomplicated period on oral BPs. One additional case is presented to illustrate that AFFs may also occur with intravenous therapy alone. We have collected these cases directly from the patients and have confirmed all of the details by access to the original medical records, including the radiology and surgery reports. Our opportunity for access is fully described in the article. Results and Opinion: Such a switch has never been investigated in a clinical trial. Based on the pharmacokinetics associated with the intravenous routes for these drugs, we present our reasoning why the untested therapy exemplified should be considered as potentially hazardous. Furthermore, we discuss the reported but rather unremarked wide individual variation in the rate of elimination of intravenously-administered BPs which may be an important factor in determining which individuals are at greatest risk of incurring an AFF.
Authors and Affiliations
W. Banks Hinshaw, Jennifer P. Schneider
Keywords
Related Articles
- EP ID EP310531
- DOI 10.9734/IJMPCR/2017/36791
- Views 87
- Downloads 0
Metoprolol-induced Psoriasiform Drug Eruption: A Case Report
Aim: We report the case of drug-induced psoriasiform eruptions in a middle aged known hypertensive and diabetic woman being treated for paroxysmal cardiac arrhythmias with metoprolol. Case Presentation: A 58-year-old kno...
A Rarely Seen Side Effect of Sulfasalazine: Yellowish Colour in Toenails
Sulfasalazine (SLZ) was the slow acting medication most often used to treat patients with ankylosing spondylitis whose symptoms were not adequately controlled with nonsteroidal anti-inflammatory drugs, exercise, and reha...
Use of Gabapentin as an Adjunct Agent in the Treatment of Neonatal Abstinence Syndrome: A Case Report
We report the use of Gabapentin (Neurontin), an anticonvulsant and analgesic, as a non-opioid adjunct agent in the treatment of a term newborn infant with neonatal abstinence syndrome (NAS). Initial treatment with methad...
Essential Thrombocythemia Complicated with Acute Myocardial Infarction
Aims: Essential thrombocythemia or thrombocytosis is an uncommon disease. It involves an overproduction of megakaryocytes in the marrow. These platelets may not function normally and can cause a...
Use of Human Embryonic Stem Cells (hESCs) in the Treatment of Glaucoma
Glaucoma is a degenerative, optic neuropathy that results in damage to the optic nerve due to increased intraocular pressure (IOP). IOP can be influenced by hypertension, body mass index, atherosclerotic disease and diab...